Base de dados : MEDLINE Pesquisa : Isquemia and Miocárdica [Palavras] Referências encontradas : 31445 [refinar] Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 3145

ir para página

1 / 31445

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 23322306 [Au] Autor: Carboni GP; Sedati P [Ad] Endereço: Department of Nuclear Cardiology, Università Campus Bio-Medico, Rome, Italy. g.carboni@unicampus.it [Ti] Título: Ventricular ectopy after exercise and occult ischaemia in a patient with multiple risk factors for ischaemic heart disease and defective anginal warning system. [So] Source: BMJ Case Rep;2013, 2013. [Is] ISSN: 1757-790X [Cp] País de publicação: England [La] Idioma: eng [Mh] Termos MeSH primário: Angina Pectoris/complicações Eletrocardiografia Teste de Esforço/efeitos adversos Exercício/fisiologia Isquemia Miocárdica/complicações Complexos Ventriculares Prematuros/etiologia [Mh] Termos MeSH secundário: Idoso Angina Pectoris/diagnóstico Diagnóstico Diferencial Humanos Masculino Isquemia Miocárdica/diagnóstico Fatores de Risco Tomografia Computadorizada por Raios X Complexos Ventriculares Prematuros/diagnóstico [Pt] Tipo de publicação: CASE REPORTS; JOURNAL ARTICLE [Em] Mês de entrada: 1305 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 130116 [St] Status: MEDLINE

2 / 31445

MEDLINE

seleciona para imprimir Fotocópia PubMed Central Texto completo Texto completo

[PMID]: 23133515 [Au] Autor: Lalu MM; McIntyre L; Pugliese C; Fergusson D; Winston BW; Marshall JC; Granton J; Stewart DJ; Canadian Critical Care Trials Group [Ad] Endereço: Department of Anesthesiology, University of Ottawa, Ottawa, Canada. [Ti] Título: Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. [So] Source: PLoS One;7(10):e47559, 2012. [Is] ISSN: 1932-6203 [Cp] País de publicação: United States [La] Idioma: eng [Ab] Resumo: BACKGROUND: Mesenchymal stromal cells (MSCs, "adult stem cells") have been widely used experimentally in a variety of clinical contexts. There is interest in using these cells in critical illness, however, the safety profile of these cells is not well known. We thus conducted a systematic review of clinical trials that examined the use MSCs to evaluate their safety. METHODS AND FINDINGS: MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials (to June 2011), were searched. Prospective clinical trials that used intravascular delivery of MSCs (intravenously or intra-arterially) in adult populations or mixed adult and pediatric populations were identified. Studies using differentiated MSCs or additional cell types were excluded. The primary outcome adverse events were grouped according to immediate events (acute infusional toxicity, fever), organ system complications, infection, and longer term adverse events (death, malignancy). 2347 citations were reviewed and 36 studies met inclusion criteria. A total of 1012 participants with clinical conditions of ischemic stroke, Crohn's disease, cardiomyopathy, myocardial infarction, graft versus host disease, and healthy volunteers were included. Eight studies were randomized control trials (RCTs) and enrolled 321 participants. Meta-analysis of the RCTs did not detect an association between acute infusional toxicity, organ system complications, infection, death or malignancy. There was a significant association between MSCs and transient fever. CONCLUSIONS: Based on the current clinical trials, MSC therapy appears safe. However, further larger scale controlled clinical trials with rigorous reporting of adverse events are required to further define the safety profile of MSCs. [Mh] Termos MeSH primário: Ensaios Clínicos como Assunto Células Mesenquimais Estromais/citologia Células Estromais/citologia Terapia Tecidual/métodos [Mh] Termos MeSH secundário: Adolescente Adulto Idoso Cardiomiopatias/terapia Doença Enxerto-Hospedeiro/terapia Humanos Masculino Meia-Idade Infarto do Miocárdio/terapia Isquemia Miocárdica/terapia Segurança do Paciente Estudos Prospectivos Ensaios Clínicos Controlados Aleatórios como Assunto Resultado de Tratamento [Pt] Tipo de publicação: JOURNAL ARTICLE; META-ANALYSIS; REVIEW [Em] Mês de entrada: 1305 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 121107 [St] Status: MEDLINE [do] DOI: 10.1371/journal.pone.0047559

3 / 31445

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 22550962 [Au] Autor: Speckauskas M; Tamosiunas A; Jasinskas V [Ad] Endereço: Department of Ophthalmology, Lithuanian University of Health Sciences, Kaunas, Lithuania. 2martynas@gmail.com [Ti] Título: Association of ocular pseudoexfoliation syndrome with ischaemic heart disease, arterial hypertension and diabetes mellitus. [So] Source: Acta Ophthalmol;90(6):e470-5, 2012 Sep. [Is] ISSN: 1755-3768 [Cp] País de publicação: England [La] Idioma: eng [Ab] Resumo: PURPOSE: To determine the prevalence of pseudoexfoliation syndrome (PEX) in Lithuanian urban population and its association with ischaemic heart disease (IHD), arterial hypertension (AH) and diabetes mellitus (DM). METHODS: In this population-based study, 1065 participants aged 45-72 years were randomly drawn from the population register of Kaunas, Lithuania. They were classified as having PEX if any pseudoexfoliation material was determined by a slit-lamp examination in at least one eye. The data were acquired from questionnaire; register of myocardial infarction, electrocardiogram, biochemical blood analyses and blood pressure measurement were used to determine IHD, AH, DM and smoking habits. Poststratification weights based on Kaunas population sex and age distribution were applied. RESULTS: Pseudoexfoliation syndrome was estimated in 9% of a population. The AH rate was higher in PEX subjects than in non-PEX subjects (p=0.017) and the rates of IHD, DM and cholesterol levels did not differ statistically significantly. Chi-square linear-by-linear association test found higher AH rate in unilateral PEX subjects and even higher AH rate in bilateral PEX subjects than in non-PEX subjects (p=0.014). Pseudoexfoliation syndrome increased odds for AH by 1.8 times (p=0.021). Median of systolic blood pressure was higher in the PEX group than in non-PEX group (p=0.04). But all associations could not be confirmed after adjusting for age. Smoking duration increased age-adjusted odds for PEX. Pseudoexfoliation syndrome did not increase risk for IHD, AH or DM. CONCLUSIONS: Pseudoexfoliation syndrome prevalence is high in Lithuania. No clear PEX association with IHD, AH and DM was proven after controlling for effect of age. [Mh] Termos MeSH primário: Diabetes Mellitus/epidemiologia Síndrome de Exfoliação/epidemiologia Hipertensão/epidemiologia Isquemia Miocárdica/epidemiologia [Mh] Termos MeSH secundário: Distribuição por Idade Idoso Pressão Sanguínea/fisiologia Diabetes Mellitus/fisiopatologia Síndrome de Exfoliação/fisiopatologia Feminino Humanos Hipertensão/fisiopatologia Pressão Intraocular/fisiologia Lituânia/epidemiologia Masculino Meia-Idade Isquemia Miocárdica/fisiopatologia Prevalência Questionários Distribuição por Sexo Acuidade Visual/fisiologia [Pt] Tipo de publicação: JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T [Em] Mês de entrada: 1211 [Cu] Atualização por classe: 130506 [Lr] Data última revisão: 130506 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 120829 [St] Status: MEDLINE [do] DOI: 10.1111/j.1755-3768.2012.02439.x

4 / 31445

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 22432469 [Au] Autor: Zhang X; Zhang X; Wang F [Ad] Endereço: Shandong University, Institute of Biochemical and Biotechnological Drugs, School of Pharmaceutical Sciences, Jinan 250012, Shandong. [Ti] Título: Intracellular transduction and potential of Tat PTD and its analogs: from basic drug delivery mechanism to application. [So] Source: Expert Opin Drug Deliv;9(4):457-72, 2012 Apr. [Is] ISSN: 1744-7593 [Cp] País de publicação: England [La] Idioma: eng [Ab] Resumo: INTRODUCTION: It has been 20 years since the discovery of the membrane-translocating property of the HIV-1 transactivator of transcription (Tat) protein. The Tat protein transduction domain (Tat PTD) is a very promising tool for non-invasive cellular import of cargos and has been successfully applied to in vitro and in vivo delivery of different therapeutic agents for the treatment of many diseases. A growing number of reports on Tat PTD-mediated delivery have extensively revealed the mechanisms involved. Yet, due to the varied conditions used, the reports on the internalization mode of Tat PTD-cargo chimera are often varied.AREAS COVERED: This article reviews the possible intracellular trafficking mechanisms of Tat PTD including its binding, cellular entry process, and the roles of participants of the cell membrane. The therapeutic applications via local administration, such as those for the treatment of skin, ocular, cardiac and cerebral diseases, are also reviewed. In addition, some novel systems built by different groups are elucidated, which are utilized to overcome the poor targeting efficiency of Tat PTD for the treatment of CNS diseases, cancer and other diseases via systemic administration.EXPERT OPINION: With the development of targeting factors, such as antibodies, some cell targeting peptides and novel polymers, Tat PTD is expected to play a more efficient and/or better tolerated therapeutic role in the drug delivery field. [Mh] Termos MeSH primário: Sistemas de Liberação de Medicamentos/métodos Produtos do Gene tat/metabolismo Transporte Proteico/fisiologia Ativação Transcricional/fisiologia [Mh] Termos MeSH secundário: Administração Cutânea Administração Oftálmica Administração Tópica Animais Cavéolas/metabolismo Membrana Celular/metabolismo Clatrina/metabolismo Endocitose/fisiologia Produtos do Gene tat/química HIV-1/metabolismo Humanos Metaloproteinases da Matriz/metabolismo Isquemia Miocárdica/quimioterapia Neoplasias/quimioterapia Peptídeos/metabolismo Pinocitose/fisiologia Estrutura Terciária de Proteína Dermatopatias/quimioterapia Transativadores/metabolismo Transdução Genética [Pt] Tipo de publicação: JOURNAL ARTICLE; REVIEW [Nm] Nome de substância: 0 (Clathrin); 0 (Gene Products, tat); 0 (Peptides); 0 (Trans-Activators); EC 3.4.24.- (Matrix Metalloproteinases) [Em] Mês de entrada: 1305 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 120426 [St] Status: MEDLINE [do] DOI: 10.1517/17425247.2012.663351

5 / 31445

MEDLINE

seleciona para imprimir Fotocópia

[PMID]: 21432822 [Au] Autor: Wilinski J; Czarnecka D; Wojciechowska W; Kloch-Badelek M; Jastrzebski M; Bacior B; Sondej T; Kusak P; Przybyla A; Kawecka-Jaszcz K [Ad] Endereço: 1st Department of Cardiology and Hypertension, Jagiellonian University Medical College, Krakow, Poland. putamen@interia.pl [Ti] Título: Clinical and classic echocardiographic features of patients with, and without, left ventricle reverse remodeling following the introduction of cardiac resynchronization therapy. [So] Source: Cardiol J;18(2):157-64, 2011. [Is] ISSN: 1897-5593 [Cp] País de publicação: Poland [La] Idioma: eng [Ab] Resumo: BACKGROUND: The aim of the study was to assess clinical and classic echocardiographic data in patients with different cardiac resynchronization therapy (CRT) outcomes. METHODS: Sixty consecutive patients (aged 66.3 ± 8.7 years, 57 men) with chronic heart failure (CHF) in New York Heart Association (NYHA) classes III-IV despite optimized pharmacotherapy, with left ventricular end-diastolic diameter (LVEDD) > 55 mm, left ventricular ejection fraction £ 35% and wide QRS complex (≥ 120 ms), including individuals with permanent atrial fibrillation (AF) and single- and dual-chamber pacing, were assessed firstly before, and secondly three months after, biventricular heart stimulator implantation (excluding three patients who died during the follow-up). Patients developing ≥ 10% reduction of left ventricular end-systolic volume (LVESV) were classified as responders to CRT. RESULTS: The group of responders (n = 34, 59.7%) and the group of non-responders (n = 23, 40.3%) did not differ regarding baseline echocardiographic parameters or in terms of clinical data of age, gender, concomitant diseases, smoking or pharmacological treatment. The differences involved higher rates of ischemic CHF background, prevalence of hypertension and permanent AF, and a higher concentration of N-terminal pro-B-type natriuretic peptide (NT-proBNP) among the non-responders. In the multivariate logistic regression analysis, NT-proBNP, body mass index (BMI) and the presence of permanent AF correlated negatively with the magnitude of LVESV reduction following CRT introduction. CONCLUSIONS: Classic echocardiographic data did not predict left ventricle reverse remodeling. Higher rates of ischemic CHF aetiology, hypertension, permanent AF and higher NT-proBNP concentration were found in the group without at least 10% LVESV reduction at the three month follow-up. NT-proBNP, BMI and the presence of permanent AF had negative effects on the magnitude of LVESV. [Mh] Termos MeSH primário: Fibrilação Atrial/terapia Fibrilação Atrial/ultrassonografia Terapia de Ressincronização Cardíaca/métodos Ecocardiografia/métodos Remodelação Ventricular [Mh] Termos MeSH secundário: Idoso Fibrilação Atrial/epidemiologia Ecocardiografia/normas Feminino Humanos Modelos Logísticos Masculino Meia-Idade Análise Multivariada Isquemia Miocárdica/epidemiologia Isquemia Miocárdica/terapia Isquemia Miocárdica/ultrassonografia Peptídeo Natriurético Encefálico/sangue Fragmentos de Peptídeos/sangue Valor Preditivo dos Testes Prevalência Prognóstico Função Ventricular Esquerda [Pt] Tipo de publicação: CLINICAL TRIAL; COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T [Nm] Nome de substância: 0 (Peptide Fragments); 0 (pro-brain natriuretic peptide (1-76)); 114471-18-0 (Natriuretic Peptide, Brain) [Em] Mês de entrada: 1305 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 110324 [St] Status: MEDLINE

6 / 31445

MEDLINE

seleciona para imprimir Fotocópia PubMed Central Texto completo Texto completo

[PMID]: 23166670 [Au] Autor: Roura S; Bagó JR; Soler-Botija C; Pujal JM; Gálvez-Montón C; Prat-Vidal C; Llucià-Valldeperas A; Blanco J; Bayes-Genis A [Ad] Endereço: ICREC Research Program, Fundació Institut dInvestigació en Ciències de la Salut Germans Trias i Pujol (IGTP), Badalona, Spain. [Ti] Título: Human umbilical cord blood-derived mesenchymal stem cells promote vascular growth in vivo. [So] Source: PLoS One;7(11):e49447, 2012. [Is] ISSN: 1932-6203 [Cp] País de publicação: United States [La] Idioma: eng [Ab] Resumo: Stem cell therapies are promising strategies to regenerate human injured tissues, including ischemic myocardium. Here, we examined the acquisition of properties associated with vascular growth by human umbilical cord blood-derived mesenchymal stem cells (UCBMSCs), and whether they promoted vascular growth in vivo. UCBMSCs were induced in endothelial cell-specific growth medium (EGM-2) acquiring new cell markers, increased Ac-LDL uptake, and migratory capacity as assessed by qRT-PCR, Western blotting, indirect immunofluorescence, and invasion assays. Angiogenic and vasculogenic potentials could be anticipated by in vitro experiments showing self organization into Matrigel-mediated cell networks, and activation of circulating angiogenic-supportive myeloid cells. In mice, following subcutaneous co-injection with Matrigel, UCBMSCs modified to co-express bioluminescent (luciferases) and fluorescent proteins were demonstrated to participate in the formation of new microvasculature connected with the host circulatory system. Response of UCBMSCs to ischemia was explored in a mouse model of acute myocardial infarction (MI). UCBMSCs transplanted using a fibrin patch survived 4 weeks post-implantation and organized into CD31(+)network structures above the infarcted myocardium. MI-treated animals showed a reduced infarct scar and a larger vessel-occupied area in comparison with MI-control animals. Taken together, the presented results show that UCBMSCs can be induced in vitro to acquire angiogenic and vasculogenic properties and contribute to vascular growth in vivo. [Mh] Termos MeSH primário: Sangue Fetal/citologia Transplante de Células-Tronco Mesenquimais/métodos Células Mesenquimais Estromais/fisiologia Infarto do Miocárdio/etiologia Isquemia Miocárdica/terapia Neovascularização Fisiológica/fisiologia [Mh] Termos MeSH secundário: Análise de Variância Animais Antígenos CD31/metabolismo Western Blotting Colágeno Meios de Cultura Combinação de Medicamentos Angiofluoresceinografia Técnica Indireta de Fluorescência para Anticorpo Humanos Laminina Camundongos Camundongos SCID Isquemia Miocárdica/complicações Proteoglicanas Reação em Cadeia da Polimerase em Tempo Real [Pt] Tipo de publicação: JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T [Nm] Nome de substância: 0 (Antigens, CD31); 0 (Culture Media); 0 (Drug Combinations); 0 (Laminin); 0 (Proteoglycans); 119978-18-6 (matrigel); 9007-34-5 (Collagen) [Em] Mês de entrada: 1305 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 121120 [St] Status: MEDLINE [do] DOI: 10.1371/journal.pone.0049447

7 / 31445

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 22120912 [Au] Autor: Kische S; Nienaber C; Ince H [Ad] Endereço: Medical Faculty, Department of Cardiology at the University Hospital Rostock, Rostock School of Medicine, Rostock, Germany. [Ti] Título: Use of four MitraClip devices in a patient with ischemic cardiomyopathy and mitral regurgitation: "zipping by clipping". [So] Source: Catheter Cardiovasc Interv;80(6):1007-13, 2012 Nov 15. [Is] ISSN: 1522-726X [Cp] País de publicação: United States [La] Idioma: eng [Ab] Resumo: Severe mitral regurgitation (MR) as a consequence of underlying left ventricular dysfunction substantially contributes to morbidity and mortality. A variety of percutaneous treatment options for mitral valve repair have been developed; however, most of these techniques are still at an early stage of clinical evaluation. Today, percutaneous edge-to-edge mitral valve repair using the MitraClip® system is the only endovascular approach that demonstrated noninferiority when compared with standard surgical repair in a randomized trial. However, a considerable number of patients with functional MR will present with extensive annulus dilatation and minimal vertical leaflet coaptation that potentially preclude them from this beneficial technology for anatomical reasons. In this report, we portray a 72-year-old man presenting with end-stage systolic heart failure and severe functional MR as a consequence of long-standing coronary artery disease. Recently, his clinical course was complicated by intractable hemodynamic instability and recurrent pulmonary edema. High predicted mortality and progressive physical decay rendered this moribund patient a candidate for salvage percutaneous mitral valve repair. During the endovascular procedure, a central systolic coaptation gap of 7 mm proved to be too wide for adequate simultaneous grasping of both leaflets. Consideration was given to an alternative approach by means of our novel "zipping technique." Through the trans-septal route, medial to lateral approximation of the tethered leaflets was successfully achieved by intentional deployment of four MitraClip® devices. With the first in-human application of four mechanical implants, a profound reduction of MR grade has been accomplished by the creation of a lateral neo-orifice with apparent acute clinical success. However, it needs to be determined whether successful application of the zipping technique leads to sustained reverse ventricular remodeling and will translate into an improved long-term prognosis. [Mh] Termos MeSH primário: Procedimentos Cirúrgicos Cardíacos/instrumentação Cardiomiopatias/etiologia Insuficiência da Valva Mitral/cirurgia Isquemia Miocárdica/complicações Instrumentos Cirúrgicos [Mh] Termos MeSH secundário: Idoso Cardiomiopatias/ultrassonografia Ecocardiografia Doppler em Cores Ecocardiografia Tridimensional Ecocardiografia Transesofagiana Desenho de Equipamento Insuficiência Cardíaca/etiologia Humanos Masculino Insuficiência da Valva Mitral/etiologia Insuficiência da Valva Mitral/ultrassonografia Tomografia Computadorizada Multidetectores Valor Preditivo dos Testes Índice de Gravidade de Doença Resultado de Tratamento [Pt] Tipo de publicação: CASE REPORTS; JOURNAL ARTICLE [Em] Mês de entrada: 1305 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 121120 [St] Status: MEDLINE [do] DOI: 10.1002/ccd.23431

8 / 31445

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 22875229 [Au] Autor: Yeung CY; Lam KS; Li SW; Lam KF; Tse HF; Siu CW [Ad] Endereço: Department of Medicine, Division of Endocrinology, The University of Hong Kong, Hong Kong, China. [Ti] Título: Sudden cardiac death after myocardial infarction in type 2 diabetic patients with no residual myocardial ischemia. [So] Source: Diabetes Care;35(12):2564-9, 2012 Dec. [Is] ISSN: 1935-5548 [Cp] País de publicação: United States [La] Idioma: eng [Ab] Resumo: OBJECTIVE: Diabetes mellitus (DM) is a well-established risk factor for coronary artery disease. Nonetheless, it remains unclear whether DM contributes to sudden cardiac death in patients who survive myocardial infarction (MI). The objective of this study was to compare the incidence of sudden cardiac death post-MI in diabetic and nondiabetic patients with no residual myocardial ischemia. RESEARCH DESIGN AND METHODS: A total of 610 consecutive post-MI patients referred to a cardiac rehabilitation program with negative exercise stress test were studied. RESULTS: Of these, 236 patients had DM at baseline. Over a mean follow-up of 5 years, 67 patients with DM (28.4%) and 76 of 374 patients without DM (20.2%) had died with a hazard ratio (HR) of 1.74 (95% CI: 1.28-2.56; P < 0.001). Patients with DM also had a higher incidence of cardiac death (1.84 [1.16-3.21]; P = 0.01), principally due to a higher incidence of sudden cardiac death (2.14 [1.22-4.23]; P < 0.001). Multiple Cox regression analysis revealed that only DM (adjusted HR: 1.9 [95% CI: 1.04-3.40]; P = 0.04), left ventricular ejection fraction (LVEF) ≤30% (3.6 [1.46-8.75]; P < 0.01), and New York Heart Association functional class >II (4.2 [1.87-9.45]; P < 0.01) were independent predictors for sudden cardiac death. Among patients with DM, the 5-year sudden cardiac death rate did not differ significantly among those with LVEF ≤30%, LVEF 31-50%, or LVEF >50% (8.8 vs. 7.8 vs. 6.8%, respectively; P = 0.83). CONCLUSIONS: Post-MI patients with DM, even in the absence of residual myocardial ischemia clinically, were at higher risk of sudden cardiac death than their non-DM counterparts. [Mh] Termos MeSH primário: Morte Súbita Cardíaca/etiologia Diabetes Mellitus Tipo 2/complicações Infarto do Miocárdio/complicações Infarto do Miocárdio/mortalidade Isquemia Miocárdica/complicações [Mh] Termos MeSH secundário: Idoso Feminino Humanos Masculino Meia-Idade Isquemia Miocárdica/mortalidade Estudos Prospectivos [Pt] Tipo de publicação: JOURNAL ARTICLE [Em] Mês de entrada: 1305 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 121122 [St] Status: MEDLINE [do] DOI: 10.2337/dc12-0118

9 / 31445

MEDLINE

seleciona para imprimir Fotocópia Texto completo SciELO Brasil

[PMID]: 22996977 [Au] Autor: Besirli K; Aydemir B; Arslan C; Kiziler AR; Canturk E; Kayhan B [Ad] Endereço: Cardiovascular Surgery Department, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey. birsenay2001@yahoo.com [Ti] Título: Calcium dobesilate may improve hemorheology in patients undergoing coronary artery bypass grafting. [So] Source: Rev Bras Cir Cardiovasc;27(2):260-6, 2012 Apr-Jun. [Is] ISSN: 1678-9741 [Cp] País de publicação: Brazil [La] Idioma: eng [Ab] Resumo: BACKGROUND: Calcium dobesilate is an angioprotective agent that has positive effects on hemorheological parameters. It is an antioxidant that increases endothelial-derived vasodilator substance secretion, there are none that analyze its effects during the postoperative period of patients undergoing myocardial revascularization. OBJECTIVE: We aimed to determine the effects of calcium dobesilate on hemorheological parameters, such as reduced glutathione and malondialdehyde in patients with ischemic heart disease undergoing myocardial revascularization in the postoperative period. METHODS: One hundred and thirty-four patients operated for coronary heart disease were included in this study. Hemorheological, oxidant and antioxidant parameters were measured two days after surgery and after a period of treatment with calcium dobesilate. Then, 500 mg of calcium dobesilate was given twice a day to one group of 68 patients for three months. The control group was composed of 66 patients who did not receive this medication. RESULTS: The increase in the erythrocyte deformability index was found to be significant compared with both the pretreatment values and with the 1st and 2nd values of the control group after calcium dobesilate administration, whereas there were no significant changes in blood viscosity, glutathione (GSH) or malondialdehyde (MDA) values after the calcium dobesilate administration. The same improvement in the CCS class was observed in patients regardless of they received the calcium dobesilate treatment. CONCLUSION: In the present investigation, the same improvement in the CCS class was observed in patients regardless of they received the calcium dobesilate treatment. Improvements with calcium dobesilate were statistically significant only in the increase in erythrocyte flexibility. [Mh] Termos MeSH primário: Dobesilato de Cálcio/uso terapêutico Ponte de Artéria Coronária Hemorreologia/efeitos de drogas Hemostáticos/uso terapêutico [Mh] Termos MeSH secundário: Idoso Análise de Variância Antioxidantes/farmacologia Antioxidantes/uso terapêutico Viscosidade Sanguínea/efeitos de drogas Dobesilato de Cálcio/farmacologia Eritrócitos/efeitos de drogas Feminino Fibrinogênio Glutationa/sangue Glutationa/efeitos de drogas Hemostáticos/farmacologia Humanos Masculino Malondialdeído/sangue Meia-Idade Isquemia Miocárdica/cirurgia Período Pós-Operatório Estatísticas não Paramétricas [Pt] Tipo de publicação: JOURNAL ARTICLE [Nm] Nome de substância: 0 (Antioxidants); 0 (Hemostatics); 20123-80-2 (Calcium Dobesilate); 542-78-9 (Malondialdehyde); 70-18-8 (Glutathione); 9001-32-5 (Fibrinogen) [Em] Mês de entrada: 1305 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 120921 [St] Status: MEDLINE

10 / 31445

MEDLINE

seleciona para imprimir Fotocópia

[PMID]: 23534108 [Au] Autor: Ciaroni S [Ad] Endereço: L'Hôpital de la Tour, Rue de I'Université I, 1205 Geneve. s.ciaroni.card@bluewin.ch [Ti] Título: [Is the coronary artery disease in woman so different from the man]. [Ti] Título: La maladie coronaire chez la femme est-elle si différente de celle de l'homme?. [So] Source: Rev Med Suisse;9(376):494-7, 2013 Mar 6. [Is] ISSN: 1660-9379 [Cp] País de publicação: Switzerland [La] Idioma: fre [Ab] Resumo: Clinical presentation and symptoms of coronary artery disease may vary according to gender. This is not true to the same extent for acute coronary syndromes. The diagnosis is more complex in women because they show less often a typical clinical picture. In spite of these gender-related clinical differences, no diagnostic strategy in the detection of the coronary artery disease is recommended for women. Because "standard" treadmill or bicycle ECG stress test has a low specificity in women, non-invasive imaging (stress echocardiography, myocardial scintigraphy or cardiac magnetic resonance) should be preferred for the evaluation of myocardial ischemia in women. [Mh] Termos MeSH primário: Doença da Artéria Coronariana/diagnóstico Teste de Esforço/métodos Isquemia Miocárdica/diagnóstico [Mh] Termos MeSH secundário: Doença da Artéria Coronariana/fisiopatologia Ecocardiografia sob Estresse/métodos Feminino Humanos Imagem por Ressonância Magnética/métodos Masculino Isquemia Miocárdica/fisiopatologia Imagem de Perfusão do Miocárdio/métodos Fatores Sexuais [Pt] Tipo de publicação: ENGLISH ABSTRACT; JOURNAL ARTICLE [Em] Mês de entrada: 1305 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 130328 [St] Status: MEDLINE

---

página 1 de 3145

ir para página

Refinar a pesquisa

Base de dados : MEDLINE

Formulário avançado

		Pesquisar	no campo
1			PalavrasDescritor de assuntoDescritor de assunto primárioLimitesAutorPalavras do títuloPalavras do resumoIdiomaPaís de publicaçãoNome de substânciaNome de pessoa como assuntoRevistaAssunto de RevistaISSNTipo de publicaçãoIdentificador únicoMês de entradaAno de publicaçãoTexto completoAtualização por classeCategoria DeCSCategoria DeCS explodidaCategoria CID-10SubSetsPais de AfiliaçãoAfiliação
2	and or and not		PalavrasDescritor de assuntoDescritor de assunto primárioLimitesAutorPalavras do títuloPalavras do resumoIdiomaPaís de publicaçãoNome de substânciaNome de pessoa como assuntoRevistaAssunto de RevistaISSNTipo de publicaçãoIdentificador únicoMês de entradaAno de publicaçãoTexto completoAtualização por classeCategoria DeCSCategoria DeCS explodidaCategoria CID-10SubSetsPais de AfiliaçãoAfiliação
3	and or and not		PalavrasDescritor de assuntoDescritor de assunto primárioLimitesAutorPalavras do títuloPalavras do resumoIdiomaPaís de publicaçãoNome de substânciaNome de pessoa como assuntoRevistaAssunto de RevistaISSNTipo de publicaçãoIdentificador únicoMês de entradaAno de publicaçãoTexto completoAtualização por classeCategoria DeCSCategoria DeCS explodidaCategoria CID-10SubSetsPais de AfiliaçãoAfiliação

Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde